Carbobenzoxy beta-alanyl-taurine

Synopsis

Carbobenzoxy Beta-Alanyl-Taurine (COBAT / Tauroxicum)

1. Identity: Chemical Name, Structure, and Common Forms

Chemical Identity

Carbobenzoxy beta-alanyl-taurine has the molecular formula C₁₃H₁₈N₂O₆S and is catalogued in PubChem under compound identification number (CID) 9927496. The compound is also widely known by its acronym COBAT (carbobenzoxy-beta-alanyl taurine), and in homeopathic registration as Tauroxicum. Its zinc salt form — zinc carbobenzoxy-beta-alanyltaurinate — is separately registered by the NIH National Center for Advancing Translational Sciences (NCATS) and carries its own InChIKey (BUDABWMEOIGHJW-UHFFFAOYSA-L). Taurox (Tauroxicum) is a homeopathic remedy ingredient made from COBAT, a modified dipeptide containing β-alanine and taurine, and is administered in nanogram-per-day doses sublingually.

Structural Composition

The structure of COBAT includes the two amino acid-derived moieties taurine and beta-alanine. More precisely, COBAT is a synthetic dipeptide conjugate in which the terminal amine of beta-alanine is protected by a carbobenzoxy (CBZ, or benzyloxycarbonyl) group, and beta-alanine is coupled to taurine (2-aminoethanesulfonic acid) via an amide bond. The carbobenzoxy moiety — a benzyl ester of a carbamic acid — distinguishes COBAT from the simpler, unprotected peptide beta-alanyl-taurine.

Compounds termed "vitaletheine modulators," which include beta-alanyl-taurine and carbobenzoxy beta-alanyl-taurine, are synthesized and added to culture media for in vitro culture of cells such as mammalian or plant cells. COBAT is classified as a vitaletheine modulator — a family of low-molecular-weight, sulfur-containing compounds believed to share structural and biological properties with the endogenous thiol vitaletheine, which is identified chemically as N-(carboxy)-beta-alanyl-cysteamine.

Synthesis

Carbobenzoxy beta-alanyl-taurine is produced by coupling β-alanine, which has its terminal amine protected with a carbobenzoxy (CBZ) group, to N-hydroxysuccinimide to produce an active ester of β-alanine, coupling two of the active esters to cystamine to produce a CBZ-protected β-alethine having an internal disulfide bond, isolating and purifying the CBZ-protected β-alethine, and reacting the CBZ-protected β-alethine with iodine to oxidize the disulfide bond to obtain carbobenzoxy beta-alanyl-taurine.

The zinc salt of COBAT is prepared by reacting the free-acid form with zinc hydroxide in water, followed by lyophilization. Recovery from this process yields a white solid corresponding to the N-carbobenzoxy-β-alanyl-taurine zinc salt. The zinc salt is the principal commercially deployed form. Its molecular formula is C₂₆H₃₄N₄O₁₂S₂Zn, as registered in PubChem CID 72941842.

Common Names and Synonyms

Carbobenzoxy beta-alanyl-taurine (full IUPAC-based name)
N-carbobenzoxy-β-alanyl-taurine (formal chemical literature designation)
CBZ-β-alanyl-taurine (abbreviated chemical name)
COBAT (common abbreviation)
Tauroxicum (homeopathic pharmacopoeial name)
Taurox / Taurox SB (principal commercial product names)
Zinc carbobenzoxy-beta-alanyltaurinate (zinc salt form, NCATS registry)
Tauroxicum (carbobenzoxy beta-alanyl taurine or COBAT) as listed in homeopathic preparation ingredient disclosures

Dosage Forms and Preparations

Taurox SB is available in multiple forms that are reported to be quickly absorbed into the body, including: (A) melting microspheres that dissolve under the tongue and are absorbed from the mouth via the oral mucosa; (B) a spray used similarly to a nasal spray; and (C) drops for sublingual use.

Taurox is prepared as a classic homeopathic medicine via a series of 6 to 7 ten-fold dilution steps ("6X" or "7X" in homeopathic nomenclature). It is administered sublingually, usually the equivalent of 1–2 drops of pure 6X or 7X held under the tongue for 15 seconds or more.

COBAT is offered by Allergy Research Group under the name Taurox SB™ and comes in two strengths: Taurox SB™ 6x Enhanced (regular strength) and Taurox SB™ 7x with Minerals (for hypersensitive individuals). A multi-ingredient homeopathic liquid preparation (Taurox 6X) also exists, containing Tauroxicum (carbobenzoxy beta-alanyl taurine or COBAT) at 6X (14%), 12X (1%), and 30X (1%) potencies as part of a broader homeopathic formula in a 20% ethanol, purified water base.

2. Historical and Traditional Context

Unlike most natural dietary ingredients covered in encyclopedic references, COBAT has no traditional botanical or ethnobotanical history of use. It is a wholly synthetic compound with no recognized use in traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, or European herbal traditions. Its history begins in the late twentieth century in an academic research context.

In the early 1990s, physician Floyd Taub, M.D., began seeking therapies to supplement or replace chemotherapy for cancer. He and colleagues identified five groups of molecules they described as enlisting the body's own defenses. The vitaletheine modulator family — of which COBAT is one member — was first described in the peer-reviewed scientific literature in 1994. The foundational paper, published in Cancer Research, was authored by Galen D. Knight, Kevin H. Laubscher, Marilyn L. Fore, Douglas A. Clark, and Terence J. Scallen, affiliated with the School of Medicine, University of New Mexico, and the Veterans Administration Medical Center, Albuquerque, New Mexico. The paper appeared in Cancer Research on November 1, 1994, volume 54, issue 21, pages 5623–5635.

A significant subsequent dispute arose over inventorship of the vitaletheine modulators. The District Court of New Mexico declared that only Drs. Knight and Scallen are inventors of the vitaletheine modulators. Despite this, COBAT (marketed as Taurox SB) was subsequently developed and commercialized primarily by Floyd Taub and associated entities, including Dovetail Technologies and CureImmune, Inc.

The compound entered the supplement market in the late 1990s and early 2000s, marketed primarily as a homeopathic immune modulator and anti-fatigue agent. It has no pre-modern, folk, or ethnobotanical precedent; its "traditional" use is therefore limited to approximately two to three decades of alternative and integrative medicine practice.

3. Relationship to Vitaletheine and Endogenous Sulfur Compounds

The vitaletheine modulator family comprises vitaletheine, defined as the free acid or salt of N-(2-mercaptoethane)-[3-(carboxyamino)-propanamide], also designated N-[3-(2-mercapto-ethanamino)-3-oxo-3,1-propanediyl]-carbamic acid; vitalethine, the oxidized (disulfide) form of this compound; and biologically active or activatable rearrangement forms of these compounds and biologically compatible salts, hydrates, and oligomers thereof.

COBAT is described as being similar to vitamins and naturally occurring sulfur compounds in mammals. The body is stated to make tiny amounts of these sulfur-based dipeptides in order to maintain various vital immune functions. Proponents of COBAT have proposed that it serves as an exogenous supplement for an endogenous regulatory molecule; however, the high potencies of the vitaletheine modulators, both in cell culture and in vivo, indicate that these or similar regulatory components, if constitutively present, probably occur endogenously at vanishingly small concentrations and may be prone to deficiency resulting from metabolic imbalances, irradiation, aging, diet, pathogenic or parasitic infections, or exposure to environmental pollutants. This endogenous deficiency hypothesis has not been independently confirmed in human clinical research.

After the body uses Taurox (COBAT), it may be digested into two beneficial amino acids, taurine and beta-alanine. Taurine helps regulate the heartbeat, maintain cell membrane stability, and prevent brain cell over-activity, while beta-alanine is a constituent of vitamin B5 (pantothenic acid) as well as coenzyme A, which play important roles in various metabolic reactions.

COBAT itself is not directly obtainable from dietary sources. When asked whether the Taurox dipeptide can be obtained from the diet, the manufacturer's position is that it is not available via the diet.

4. Key Constituents and Proposed Mechanisms of Action

Structural and Chemical Properties

COBAT (free acid form, C₁₃H₁₈N₂O₆S; molecular weight approximately 334 Da) and its zinc salt (C₂₆H₃₄N₄O₁₂S₂Zn) are sulfur-containing, low-molecular-weight synthetic dipeptides. The presence of both a sulfonyl group (from taurine's sulfonic acid moiety) and the carbobenzoxy protecting group distinguishes COBAT structurally from simpler amino acids and from the parent unprotected dipeptide beta-alanyl-taurine.

Proposed Immune Modulation via Cytokines

The predominant proposed mechanism of action for COBAT is immune modulation, primarily through effects on cytokine balance. Taurox SB is characterized as an immune modulator that acts by improving the functioning of the immune system via cytokines, which are messenger molecules controlling the immune system, helping the body to fight bacterial and viral infections and to overcome the fatigue associated with illnesses.

In vitro studies on human cells have elaborated specific immunological endpoints. Taurox was reported to enhance components of early T cell activation, including increased intracellular calcium, up-regulation of expression of the CD69 T cell activation marker, enhanced proliferation of peripheral mononuclear cells in culture, and increased granzyme levels. Tumor necrosis factor alpha (TNF-alpha) and interferon gamma messenger RNA were up-regulated in quiescent cells and decreased in exogenously stimulated cells. This bidirectional effect is central to COBAT's characterization as an immune modulator rather than a simple immune stimulant.

Researchers at the University of Maryland found that COBAT stimulated inactive immune cells, yet returned overly activated immune cells to more normal activity. This "adaptogenic" quality — both up-regulating and down-regulating immune activity depending on the basal state of the cell — is frequently cited as its distinctive feature, though independent replication of these specific findings in peer-reviewed publications is limited.

Erythropoiesis and Hematopoietic Effects

The 1994 Cancer Research publication by Knight et al. reported on the erythropoietic activity of vitaletheine modulators (the broader family of which COBAT is one member). Novel compounds based upon the thiol N-(carboxy)-β-alanyl-cysteamine (vitaletheine) have strikingly potent and seemingly diverse biological activities. Concentrations of vitaletheine modulators from 1 femtograms/ml to 100 picograms/ml medium were shown to regulate red blood cell (RBC) production from progenitors initially deprived of erythropoietin. Similarly, as little as attograms/ml concentrations of the disulfide vitalethine stimulate immunological responses of murine splenocytes toward sheep RBC in a hemolytic plaque assay. These results are derived from animal and cell culture experiments, not from human clinical studies.

Anti-Tumor Effects (Animal Models)

Dosages of vitalethine as low as femtograms/kg substantially diminished tumor size and incidence and increased survival to 80% in mice inoculated with a uniformly fatal melanoma (Cloudman S-91). A preliminary probe of the benzyl derivative of vitalethine in a myeloma model (NS-1) suggests efficacy (100% survival) as well. The "benzyl derivative of vitalethine" referred to in this context corresponds to COBAT. These are exclusively animal model findings; no human clinical oncology trials have been published for COBAT.

In Vitro Cell Culture Properties

Compounds termed vitaletheine modulators, which include beta-alanyl-taurine and carbobenzoxy beta-alanyl-taurine, are synthesized and added to culture media for in vitro culture of cells. The compounds support cell vitality, and provide increased cellular life span, increased cellular bioproductivity, improved cellular function, and adaptation of resistant cells to culturing. The compounds further delay senescence, optimize growth and maturation, and increase population doublings. These effects are described in the context of in vitro cell culture applications, not of human supplementation.

Mitochondrial Energy Production (Proposed)

These sulfur-dependent biochemical processes have been described as essential for the first part of energy production by mitochondria, which are the part of the cell that converts organic matter into fuel for the cell. This mechanism has been proposed by product developers to explain the anti-fatigue effects, but the specific mechanistic pathway linking COBAT to mitochondrial ATP production has not been validated in independent peer-reviewed human research.

Molecular Mechanism: Interactions with Endogenous Effectors

Possible molecular mechanisms of action, including interactions with peptidyl hormones, other endogenous effectors, and xenobiotic and pharmaceutical compounds, are explored in the primary literature. The modulators appear to function at least in part by providing a stimulus generic to a broad variety of cells which optimizes cellular production and viability. A precise receptor-binding or enzyme-inhibitory mechanism has not been definitively established in the published literature.

5. Scientific Evidence by Area of Use

5.1 Fatigue (General and Disease-Associated)

Claimed use and population: While not indicated to treat any disease, COBAT is used to manage general fatigue, chronic fatigue-related syndromes (CFSs), and the fatigue that accompanies illness.

Clinical evidence — pre-market trials: In a small clinical trial, COBAT was found to be effective for reducing fatigue in approximately 90% of patients with chronic fatigue, hepatitis C, or cancer. Initial clinical trials of Taurox SB (containing COBAT) showed that over 90% of patients with moderate to severe fatigue experienced a reduction in fatigue after taking it for 3–6 weeks or longer. The specific publications reporting these trials are primarily from Floyd Taub and collaborators, presented at conferences including the 2003 Whole Person Healing Conference in Bethesda, MD. The trials appear to be small, uncontrolled or incompletely reported, and have not been published in indexed peer-reviewed journals according to available literature searches.

FACIT-F Score Improvement: EPO (erythropoietin) gives on average a less than 5 point overall improvement in the FACIT-F (0–53 point) fatigue score, while Taurox provided on average a 12 point improvement in the score in pre-market clinical studies. An improvement of 3–5 points is considered to be clinically meaningful. However, this comparison is made without head-to-head trial data, and the Taurox figure derives from internal, unpublished pre-market data.

Post-market / home-use survey: Taurox has been reported to reduce fatigue in patients with HCV, cancer, Post-Lyme/Chronic Lyme Disease, CFS, and Fibromyalgia, and clinical trials demonstrated improvement in quality-of-life (QOL) measures in addition to a reduction in fatigue. However, clinical trials often report better results than post-marketing studies, and a home-use study was conducted in a generally healthier population not subject to clinical trial selection and the attendant healing environment. Users of Taurox in this survey reported significant improvement in several QOL measures; neuroimmunologic symptoms, especially fatigue, improved.

Evidence strength assessment: The evidence for COBAT's anti-fatigue effects is preliminary and weak. No published, peer-reviewed, adequately powered randomized controlled trials (RCTs) with COBAT as a standalone active ingredient have been identified in indexed databases. The 90% response rate figures frequently cited originate from small, non-independently-replicated trials with methodological limitations. Post-marketing data consists of patient surveys, which are prone to selection bias and do not constitute controlled evidence.

5.2 Homeopathic Proving Trial

In March 2001, 39 volunteers completed the first homeopathic proving trial for Taurox. The study was conducted by David Riley, M.D., associate clinical professor at the University of New Mexico Medical School, editor-in-chief of the peer-reviewed medical journal Alternative Therapies in Health and Medicine, and co-founder of the Integrative Medicine Institute.

In this double-blind, placebo-controlled trial, 92% of the patients given Taurox had significant physiological effects, versus 26% of the patients given a placebo. None of the 39 normal volunteers reported serious adverse events.

Evidence strength assessment: A homeopathic proving trial is designed to characterize subjective effects of a substance in healthy volunteers, not to demonstrate therapeutic efficacy in disease states. The trial used 39 subjects — a very small sample. The primary outcome (physiological effects as judged by a blinded investigator) was not measuring efficacy against a clinical endpoint such as fatigue severity scores. This study cannot be taken as evidence of clinical efficacy in any condition, and has not, to the best of available evidence, been published in a peer-reviewed, indexed journal.

5.3 Fibromyalgia and Chronic Fatigue Syndrome (CFS)

Taurox has been reported to reduce fatigue in patients with CFS and Fibromyalgia. The proposed mechanism involves rebalancing of cytokine levels: at the 38th annual meeting of the American Academy of Environmental Medicine in 2003, Aristo Vodjani, Ph.D., of ImmunoScience Laboratories presented studies on 2,500 patients with chronic fatigue syndrome, fibromyalgia, and Gulf War Syndrome — all illnesses characterized by fatigue, brain fog, pain, and depression — and found these syndromes had similar cytokine imbalances that often persisted even after the initiating agent was gone; thus, the best therapeutic approach was considered to be one favoring the rebalancing of cytokine levels.

Evidence strength assessment: The application of COBAT to CFS and fibromyalgia rests on the plausible hypothesis that cytokine dysregulation mediates fatigue in these conditions, combined with the claim that COBAT normalizes cytokine profiles. There are no independently published, peer-reviewed RCTs specifically in fibromyalgia or CFS populations using COBAT as the intervention. Evidence is very preliminary and indirect.

5.4 Hepatitis C Virus (HCV)-Associated Fatigue

Taurox has been reported to reduce fatigue in patients with HCV. COBAT is described as effective in reducing fatigue associated with Hepatitis C (HCV). No published, peer-reviewed RCT in HCV patients has been identified. Evidence for this application is anecdotal and uncontrolled, based on observations from clinical practice and marketing materials authored by the compound's developers.

5.5 Neoplastic Disease (Cancer) — Animal Evidence Only

In vivo studies where Taurox SB was the sole agent showed potent anti-tumor effects against melanoma and myeloma models at low doses with negligible toxicity. These studies, referenced from Knight et al. (1994), used murine models. Animal studies evidence that vitaletheine modulators show promise as lifetime treatments for myeloma and melanoma, and observations indicate these compounds should impact therapy for several different types of human cancers.

Evidence strength assessment: All oncology-relevant evidence for COBAT is pre-clinical — confined to animal tumor models and in vitro cell culture. No human clinical trials investigating COBAT's effects on cancer have been published. The extrapolation from femtogram-level anti-tumor activity in murine models to human benefit has not been substantiated.

5.6 Immune Function and Allergies

Preliminary data suggest that COBAT may also decrease the frequency of allergy symptoms, and it may modulate cytokines in order to reduce fatigue and allergies. Conditions involving disruptions of the immune system and altered cytokine levels can result in significant decreases in energy levels.

Taurox is designed to modulate the immune system, enhancing an effective immune response without overstimulating it. The bidirectional modulation claim — stimulating an underactive immune system and calming an overactive one — is supported only by in vitro data.

Evidence strength assessment: Very preliminary. No published clinical trials on allergy outcomes using COBAT have been identified.

5.7 In Vitro Cell Culture Applications (Scientific/Biotechnological)

The most robustly documented application of COBAT is in biotechnology and cell biology research. The compounds of the vitaletheine modulator family are useful for promoting phenotypic expression and vitality of cells in culture, including the promotion of increased cellular lifespan in culture, the promotion of increased cellular bioproductivity in culture, the promotion of improved cellular function in culture, and the adaptation of resistant cells to culture — broadly enabling the vitality of cells in culture for purposes such as efficient and long-term in vitro production of cell products for commercial or research purposes. These applications are covered under US patents 6,096,536 and 6,323,025, both assigned to the inventors Knight and Scallen.

6. Body Systems and Health Areas Associated with COBAT

Immune system: Proposed modulation of T-cell activation, cytokine balance (TNF-alpha, interferon gamma), and CD69 expression.
Hematopoietic system: Regulation of erythropoiesis (red blood cell production from progenitors) observed in vitro and in animal models.
Energy metabolism / mitochondria: Proposed role in the early stages of mitochondrial energy production (ATP synthesis), with putative relevance to fatigue symptoms.
Neurological / neuroimmunomodulation: Fatigue, "brain fog," and malaise associated with immune-mediated conditions are target symptoms.
Oncological (pre-clinical only): Anti-tumor effects in melanoma and myeloma murine models.
Allergic / hypersensitivity conditions: Cytokine modulation proposed as a basis for reducing allergic reactivity.

7. Dosage Forms and Reported Dosages

Because COBAT is prepared and used as a homeopathic medicine, the quantities of active compound in final preparations are extremely small.

Taurox is administered in nanogram/day doses sublingually.
Taurox is prepared via a series of 6 to 7 ten-fold dilution steps (6X or 7X in homeopathic nomenclature) and is typically administered sublingually as the equivalent of 1–2 drops of pure 6X or 7X held under the tongue for 15 seconds or more.
The suggested dose for Integra TH (another trade name for the same product) of 15 drops per day provides twice the amount of Taurox SB used in the clinical trial, which was 1 drop of 100% Taurox SB.
For adults and children at least 15 years of age, the suggested use of Taurox high-potency pellets is to dissolve 2 pellets completely under the tongue each morning, or as directed by a healthcare professional.
In toxicology studies in mice (not in human preparations): Single-dose studies of Taurox SB in adult male and female CD-1 mice suggested a maximally tolerated dose (MTD) of about 150 mg/kg administered as an intravenous (IV) bolus; acute toxicology studies did not demonstrate an acute lethal response until doses exceeding 133 mg/kg were reached.
In animal sub-chronic studies: No toxic side effects were observed following either oral or subcutaneous daily doses of 400 µg/kg of Taurox SB for 9 days in animals; during the 14-day post-administration period, all animals gained appropriate weight compared to saline-injected controls, and there was no morbidity or mortality. Following euthanasia, there were no abnormal findings in gross necropsies.

No human pharmacokinetic studies defining absorption, distribution, metabolism, or elimination (ADME) parameters for COBAT at therapeutic doses have been identified in the published literature.

8. Safety Considerations and Interactions

General Toxicology Profile

Toxicology studies (in animals) revealed a therapeutic index of ten million for COBAT. Similar findings were obtained in animals receiving 2000 mg/kg orally for 14 days. These preclinical findings are frequently cited to support the compound's safety, though human safety data from controlled trials is extremely limited.

Reported Adverse Effects

Some patients experience headache, joint aches, and discomfort in the chest when starting the use of Taurox SB. These are attributed by proponents to immune activation rather than toxicity; they have not been characterized in a controlled trial setting. In the 2001 homeopathic proving trial, none of the 39 normal volunteers reported serious adverse events.

Regulatory Status and FDA Registration

While Taurox is FDA-registered, homeopathic products are not reviewed by the FDA for efficacy. This means that COBAT-containing preparations are regulated as homeopathic OTC drug products but have not undergone the FDA's efficacy review process applicable to conventional pharmaceuticals.

Known Contraindications

Product labeling and prescribing information for COBAT-containing products disclose several contraindications based on its immune-modulating mechanism:

Do not take with steroids or immunosuppressive agents, which will inhibit the effects.
Do not use if pregnant or breast-feeding.
Do not use if you have had an organ transplant.
Do not take if you have an autoimmune condition without professional consultation.

OTC preparations such as aspirin, acetaminophen, or others for aches and pains are stated as not likely to decrease the benefits.

Drug Interactions

The primary interaction of documented concern is with immunosuppressive drugs. Because COBAT is proposed to function as an immune activator and modulator, concurrent use of corticosteroids, calcineurin inhibitors, or other immunosuppressants may antagonize its putative effects. This interaction concern is stated on product labeling but has not been studied pharmacologically in controlled experiments. No independent pharmacokinetic or pharmacodynamic drug interaction data have been published for COBAT.

Disputed Synthesis and Product Authenticity

A notable scientific controversy concerns whether commercially available COBAT products contain authentic COBAT or an artifact of the synthesis process. The conclusions of Taub et al. are described as suspect by one of the original inventors due to their alleged use of the wrong solvent (acetone rather than acetonitrile) in the synthetic procedures for beta-alethine and ultimately vitalethine. The artifactual use of acetone is suspected of producing a Schiff base artifact of vitalethine capable of mimicking the tautomerism of vitalethine; chemical analogues of natural compounds, such as this Schiff base analogue of vitalethine, are known to inhibit the desirable activities of the natural substances. This dispute between the original inventors (Knight and Scallen) and subsequent commercializers (Taub et al.) has not been resolved through independent published analytical chemistry comparison of the two synthetic products.

Limitations of Evidence Base

The overall evidence base for COBAT as a human health supplement is substantially limited by the following factors, which are important for accurate evaluation:

The most cited clinical data (90% fatigue reduction rates) derive from small, non-independently-replicated trials and were predominantly published in conference proceedings or proprietary reports rather than peer-reviewed indexed journals.
Mechanistic studies in human cells and animals are real, but extrapolation to therapeutic benefit in humans at homeopathic dilutions is not supported by conventional pharmacological principles.
No systematic reviews, meta-analyses, Cochrane reviews, or large-scale RCTs have been published for COBAT.
No independent government health body (NIH ODS, NCCIH, EMA, EFSA) has issued a monograph or formal evidence review for COBAT.
The compound is not listed in standard pharmacopeias (USP, European Pharmacopoeia, WHO Monographs, or ESCOP).